Role of XXXX in insulin resistance.

@entity1007 @entity6 @entity101 @entity731 @entity5710 @entity2299 @entity409 @entity6864 @entity12721 @entity842 @entity209 @entity453 @entity413 @entity165
The endothelium regulates vascular tone through the release of vasodilating and vasoconstricting substances. The most important of these vasodilating substances is @entity842 (NO), which is also vascular protective and inhibits inflammation, oxidation, vascular smooth muscle cell proliferation, and migration. Damage to the endothelium causes @entity409 with impaired release of NO and loss of its antiatherogenic protection. Traditional risk factors for @entity453 , including @entity6 , @entity1007 , @entity101 , and low levels of high-density lipoprotein @entity165 , are associated with @entity409 and thus promote the atherogenic process. More recently, insulin resistance in the absence of overt @entity6 or the @entity209 has been associated with @entity409 . This association provides evidence that the @entity731 process may actually begin earlier in the spectrum of insulin resistance, ultimately resulting in a progression of the @entity209 to @entity5710 and then to type 2 @entity6 . Aggressive treatment of @entity2299 and @entity101 , even before the onset of type 2 @entity6 , would appear prudent in decreasing the progression of the @entity731 process. The @entity12721 are @entity6864 agonists that improve @entity413 and lipid metabolism. These agents have recently been shown to improve endothelial function in the early stages of insulin resistance. Results from ongoing trials with @entity12721 will reveal whether they will also reduce cardiovascular end points.
